We are live on ! Find out more
ALLO icon

Allogene Therapeutics
ALLO

95 hedge funds and large institutions have $1.87B invested in Allogene Therapeutics in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

371% more call options, than puts

Call options by funds: $10.7M | Put options by funds: $2.28M

44% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 25

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

1% more funds holding

Funds holding: 94 → 95 (+1)

1% more capital invested

Capital invested by funds: $1.85B → $1.87B (+$22.8M)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

0.25% less ownership

Funds ownership: 56.67% → 56.42% (-0.25%)

Holders
95
Holders Change
+1
Holders Change %
+1.06%
% of All Funds
2.08%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
12
Increased
36
Reduced
25
Closed
10
Calls
$10.7M
Puts
$2.28M
Net Calls
+$8.45M
Net Calls Change
+$7.85M

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$14.4M
2
Capital World Investors
Capital World Investors
California
+$14.3M
3
BlackRock
BlackRock
New York
+$12.6M
4
WCM
Wildcat Capital Management
New York
+$10.7M
5
Norges Bank
Norges Bank
Norway
+$7.85M

Top Sellers

Rank Fund Capital Flow
1
VM
VV Manager
Massachusetts
-$51.2M
2
CBA
Coastal Bridge Advisors
Connecticut
-$9.43M
3
State Street
State Street
Massachusetts
-$7.39M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$6.42M
5
DP
DSAM Partners
United Kingdom
-$4.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
Axa
26
Axa
France
$4.68M -$8.63K -303 -0.2%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$4.03M +$398K +13,979 +10%
Macquarie Group
28
Macquarie Group
Australia
$4M – – –
Principal Financial Group
29
Principal Financial Group
Iowa
$3.69M +$4.16K +146 +0.1%
DP
30
DSAM Partners
United Kingdom
$2.93M -$4.52M -158,828 -60%
Goldman Sachs
31
Goldman Sachs
New York
$2.87M +$754K +26,474 +34%
AG
32
Artal Group
Luxembourg
$2.73M -$2.85M -100,000 -50%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$2.68M +$2.25M +78,972 +409%
HAM
34
HHR Asset Management
New Jersey
$2.42M – – –
CIA
35
Capital Impact Advisors
Massachusetts
$2.06M +$306K +10,756 +17%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$1.65M +$25.1K +882 +1%
Rafferty Asset Management
37
Rafferty Asset Management
New York
$1.62M -$486K -17,057 -22%
State of Wisconsin Investment Board
38
State of Wisconsin Investment Board
Wisconsin
$1.59M +$746K +26,200 +82%
TD Asset Management
39
TD Asset Management
Ontario, Canada
$1.58M – – –
VIA
40
Vident Investment Advisory
Georgia
$1.44M -$43K -1,509 -3%
RhumbLine Advisers
41
RhumbLine Advisers
Massachusetts
$1.4M +$3.36K +118 +0.2%
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.23M – – –
Citigroup
43
Citigroup
New York
$1.16M -$1.45M -50,790 -55%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$1.08M – – –
SG Americas Securities
45
SG Americas Securities
New York
$1.05M +$1.09M +38,370 New
Bank of America
46
Bank of America
North Carolina
$1.02M -$953K -33,470 -47%
Russell Investments Group
47
Russell Investments Group
United Kingdom
$996K +$1.04M +36,556 New
SAM
48
Shikiar Asset Management
New York
$954K -$239K -8,400 -19%
Barclays
49
Barclays
United Kingdom
$870K +$196K +6,883 +28%
Morgan Stanley
50
Morgan Stanley
New York
$864K +$626K +21,967 +226%
1
2
3 4 5

ALLO Hedge Fund Activity: Q3 2019 in Review

95 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q3 2019, worth a combined $1.87B — up 1.2% from $1.85B a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ALLO positions and 10 closed out — a net gain of 2 holders — while 36 added to existing stakes and 25 trimmed.

The largest buyer was Vanguard Group, adding an estimated $14.4M. The largest seller was VV Manager, cutting an estimated $51.2M.

  • 95 institutional investors held Allogene Therapeutics (ALLO) as of Q3 2019, up from 94 in Q2 2019.
  • Funds reported $1.87B of Allogene Therapeutics stock for Q3 2019, up 1.2% quarter-over-quarter.
  • 12 funds opened new Allogene Therapeutics positions in Q3 2019 and 10 closed out, a net change of +2 holders.
  • The largest Allogene Therapeutics buyer in Q3 2019 was Vanguard Group, an estimated $14.4M added.
  • The largest Allogene Therapeutics seller in Q3 2019 was VV Manager, an estimated $51.2M sold.

Based on aggregated 13F filings for Q3 2019.